Summit Biosciences Competitors and Similar CompaniesClear all

Summit Biosciences's competitors and similar companies include McKesson Europe, Alkem Laboratories, Sanofi Pasteur and Macleods Pharmaceuticals.

	Summit Biosciences Summit Biosciences is a pharmaceutical company that develops, manufactures and commercializes prescription nasal spray products.	McKesson Europe McKesson Europe is a trading company that provides logistics and services in the pharmaceutical and healthcare sector.	Alkem Laboratories Alkem Laboratories is a pharmaceutical company that operates globally.	Sanofi Pasteur Sanofi Pasteur is a pharmaceutical company that develops, manufactures, and supplies vaccines.	Macleods Pharmaceuticals Macleods Pharmaceuticals is a company involved in pharmaceutical research, development, and manufacturing.
Founding Date	Founding Date 2008	Founding Date 1835	Founding Date 1973	Founding Date 1989	Founding Date 1986
Type	Type Private	Type Subsidiary	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma	Tags Healthcare drug development pharma
Locations	Locations Lexington, US HQ	Locations Stuttgart, DE HQ	Locations HQ Mumbai, IN Almaty, KZ Makati, PH	Locations Lyon, FR HQ	Locations Mumbai, IN HQ Almaty, KZ Kuala Lumpur, MY Taguig, PH Alberton, ZA Kyiv, UA see more
Employees	Employees 51	Employees 26,329	Employees 14,331	Employees 6,7454% increase	Employees 11,1491% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €18b (FY, 2022)	Revenue (est.) N/A	Revenue (est.) €2.8b (FY, 2021)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €16.1b (FY, 2022)	Cost of goods N/A	Cost of goods €505m (FY, 2021)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €1.9b (FY, 2022)	Gross profit N/A	Gross profit €2.3b (FY, 2021)	Gross profit N/A
Net income	Net income N/A	Net income (€867.4m) (FY, 2022)	Net income N/A	Net income €605m (FY, 2021)	Net income N/A